BioCryst Pharmaceuticals | BCRX - 贸易债权人



金融业
股票价格
USD
资产
USD 465.05M
现金及等价物
USD 171.59M
销售成本
USD 9.52M
流动资产
USD 373.63M
流动负债
USD 195.39M
债务
USD 828.6M
股息收益率
0
EBIT
USD 260.39M
EBITDA
USD 51.7M
员工
536
EPS每股收益
USD 1.17
股本和储备
USD -553.84M
销售毛利
USD 153.05M
债务利息支出
USD 14.14M
利息收入
USD -0.13
贷款资金
USD 395.2M
市值
USD 1.8B
净收入
USD 245.85M
营业费用
USD -553.84M
营业利润
USD 260.39M
普通股股本
USD 213.06M
PE价格收益
6.06
税前利润
USD 248.02M
销售收入
USD 406.56M
销售和管理费用
USD 95.78M
股票
USD 5.99M
贸易债权人
USD 10.96M
应收帐款人
USD 106.82M


贸易债权人 更改 日
Alnylam Pharmaceuticals USD 126.63M 10.91M 2026-03
BioCryst Pharmaceuticals USD 10.96M 4.87M 2026-03
Chugai Pharma JPY 107.52B 19.72B 2026-03
Daiichi Sankyo JPY 568.5B 16.84B 2025-12
DBV Technologies USD 39.82M 972K 2025-09
Enanta Pharmaceuticals USD 1.88M 63K 2025-12
Gilead Sciences USD 645M 70M 2026-03
GlaxoSmithKline GBP 14.34B 1.05B 2026-03
Glaxosmithkline GBP 20.72B 346.14M 2025-12
Incyte USD 228.62M 1.41B 2026-03
Ionis Pharmaceuticals USD 26.03M 2.05M 2026-03
Karyopharm Therapeutics USD 4M 1.39M 2025-12
Neurocrine Biosciences USD 691.3M 145.8M 2026-03
Novavax USD 16.1M 8.48M 2026-03
PTC Therapeutics USD 25.48M 20M 2026-03
Regeneron Pharmaceuticals USD 1.03B 4.81B 2026-03
Roche Holding CHF 5.78B 1.27B 2025-12
Sarepta Therapeutics USD 70.38M 210.46M 2026-03
Ultragenyx Pharmaceutical USD 42M 11M 2026-03
Vertex Pharmaceuticals USD 3.47B 40.6M 2026-03